Lignocainum Hydrochloricum Wzf

Lidocaine Hydrochloride, the active ingredient in Lignocainum Hydrochloricum Wzf, is a local anesthetic presented as a sterile solution for epidural, infiltration, and intrathecal use. It provides reversible loss of sensation in targeted tissues and is employed in surgical, diagnostic, and pain‑relief procedures for adult patients.

GNH USA supplies Lignocainum Hydrochloricum Wzf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product complies with European Union quality standards and is distributed under strict Good Distribution Practice guidelines to meet the needs of modern healthcare facilities.

Lignocainum Hydrochloricum Wzf (lidocaine) is used in the local anesthetic pathway to provide reversible nerve block for various clinical situations.

Local anesthesia: provides surface or mucosal numbness for minor surgical or diagnostic procedures. Regional anesthesia: enables nerve block techniques for surgeries requiring anesthesia of larger body regions. Pain management: used to alleviate acute procedural pain or postoperative discomfort.

Lignocainum Hydrochloricum Wzf may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Burning or stinging at the injection site - Tingling or numbness extending beyond the target area - Dizziness or light‑headed feeling - Transient hypotension

Serious or Rare Side Effects: - Allergic reactions such as rash, urticaria, or anaphylaxis - Cardiac arrhythmias including ventricular tachycardia - Central nervous system toxicity presenting as seizures or loss of consciousness - Methemoglobinemia leading to cyanosis

When using Lignocainum Hydrochloricum Wzf, clinicians should observe specific safety measures to minimise risk.

Allergy assessment: verify patient has no known hypersensitivity to lidocaine or amide‑type anesthetics. Dose optimisation: use the lowest effective concentration and volume for the intended procedure. Cardiovascular monitoring: observe heart rate and blood pressure during regional blocks. Avoid in severe heart block: contraindicated in patients with high‑grade atrioventricular block without pacing. Caution in hepatic impairment: reduce dose or extend interval in patients with significant liver disease. Store at ambient temperature: keep in original container, protect from moisture and light.

Lignocainum Hydrochloricum Wzf can interact with other medicines, altering its safety or efficacy.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase systemic lidocaine toxicity. - Beta‑blockers: can potentiate hypotension and bradycardia when combined with regional anesthesia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., rifampin, carbamazepine): may reduce lidocaine effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk when used with neuraxial techniques.